FDA
Stories
-
FDA finalizes exemption for certain class II clinical toxicology test systems
The FDA issued a final order exempting specific class II clinical toxicology test systems from premarket notification (510(k)) requirements, effective October 6, 2026. This exemption will decrease regulatory burdens on the medical device industry and will eliminate private costs and expenditures required to comply with certain Federal regulations.
-
FDA seeks public input to support ibogaine research
The FDA issued a request for information (RFI) to gather comments on early-phase clinical trial design for ibogaine drug products, including dose selection, safety monitoring and ethical oversight. Stakeholders have 45 days to submit comments, with the deadline on Friday, November 20, 2026.
-
FDA requests nominations for voting members of advisory committees
The agency is seeking qualified individuals to fill scientific, technical, professional, and other voting-member positions. The notice was published October 1, 2026.
-
FDA requests nominations for consumer representatives on advisory committees
The FDA is requesting nominations for voting and/or nonvoting consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. Nominations will be accepted for current vacancies and for those that will or may occur through December 31, 2026, with interest letters due by November 16, 2026.
-
FDA determines ISTURISA not withdrawn from sale
The FDA has determined that ISTURISA (osilodrostat) tablets, 10 mg, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications for osilodrostat tablets, 10 mg if all other legal and regulatory requirements are met.
-
FDA classifies flushing and storage solution for vascular autografts at room temperature as class II
The order places the device type into class II (special controls), which the FDA has determined will provide a reasonable assurance of the safety and effectiveness of the device. The FDA said the action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
-
FDA approves first pediatric heart valve built to be expanded as a child grows
Edwards Lifesciences' Autus Size-Adjustable Valve is also the first valve approved in the U.S. with polymeric leaflets instead of animal tissue.
-
FDA approves Emcitate, the first treatment for MCT8 deficiency
Egetis Therapeutics' tiratricol treats the excess blood thyroid hormone of Allan-Herndon-Dudley syndrome. The company also received a rare pediatric disease priority review voucher.
-
FDA rewrites drug safety rules to say “nonclinical,” not “animal,” testing
A direct final rule takes effect February 4, 2027, unless the agency receives significant adverse comments by December 7, 2026.
-
FDA approves Fayuvi, the first gene therapy for Sanfilippo syndrome type A
Ultragenyx's one-time AAV9 infusion received standard full approval for children with MPS IIIA, and the company received a priority review voucher.